{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:35:57Z","timestamp":1789785357564,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The long-term effects of long-acting growth hormone (LAGH) analogues on glucose metabolism in adult growth hormone deficiency (AGHD) are not known. We investigated the impact of LAGH somapacitan, administered once-weekly, on glucose metabolism in patients with AGHD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In post hoc-defined analyses, we compared the effects of somapacitan with daily growth hormone (GH) and placebo on fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR) and beta-cell function (HOMA-\u03b2) in patients with AGHD across a unique data set from three phase 3 randomized controlled trials (REAL 1, REAL 2 and REAL Japan).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>No new cases of diabetes mellitus were reported with somapacitan. Among GH-na\u00efve patients (n\u2009=\u2009120 somapacitan, n\u2009=\u2009119 daily GH), higher changes from baseline in FPG, HOMA-IR and fasting insulin levels were observed with daily GH versus somapacitan at 34\u00a0weeks, but not at 86\u00a0weeks. HbA1c and HOMA-\u03b2 did not differ between groups at either timepoint. Among treatment-na\u00efve patients, sex, age, fasting insulin, glucose tolerance status and body mass index did not influence changes in glucose metabolism. In previously treated patients (REAL 1 extension: n\u2009=\u200951 somapacitan, n\u2009=\u200952 daily GH; REAL 2: n\u2009=\u200961 and n\u2009=\u200931, respectively; REAL Japan: n\u2009=\u200946 and n\u2009=\u200916, respectively), the difference in changes from baseline were not statistically significant between somapacitan and daily GH for any glucose metabolism parameters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Somapacitan, compared with daily GH, did not adversely affect glucose metabolism up to 86\u00a0weeks in a large cohort of treatment-na\u00efve or previously treated patients with AGHD.<\/jats:p>\n                <jats:p>Trial registrations (date of registration): NCT02229851 (2 September 2014), NCT02382939 (3 March 2015), NCT03075644 (7 March 2017).\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11102-022-01283-3","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T20:20:49Z","timestamp":1668543649000},"page":"57-72","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency"],"prefix":"10.1007","volume":"26","clinical-trial-number":[{"clinical-trial-number":"nct02229851","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02382939","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03075644","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1337-9246","authenticated-orcid":false,"given":"Yutaka","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4359-4622","authenticated-orcid":false,"given":"Beverly M. K.","family":"Biller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2508-9588","authenticated-orcid":false,"given":"Ken K. Y.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2210-0366","authenticated-orcid":false,"given":"Michael H\u00f8jby","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0290-9803","authenticated-orcid":false,"given":"Navid","family":"Nedjatian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Sv\u00e6rke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8169-2728","authenticated-orcid":false,"given":"Kevin C. J.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3484-8440","authenticated-orcid":false,"given":"Gudmundur","family":"Johannsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"1283_CR1","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1210\/jcem.77.6.8263158","volume":"77","author":"G Amato","year":"1993","unstructured":"Amato G, Carella C, Fazio S, La Montagna G, Cittadini A, Sabatini D, Marciano-Mone C, Sacc\u00e1 L, Bellastella A (1993) Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 77:1671\u20131676. https:\/\/doi.org\/10.1210\/jcem.77.6.8263158","journal-title":"J Clin Endocrinol Metab"},{"key":"1283_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.beem.2017.03.005","volume":"31","author":"C Di Somma","year":"2017","unstructured":"Di Somma C, Scarano E, Savastano S, Savanelli MC, Pivonello R, Colao A (2017) Cardiovascular alterations in adult GH deficiency. Best Pract Res Clin Endocrinol Metab 31:25\u201334. https:\/\/doi.org\/10.1016\/j.beem.2017.03.005","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1283_CR3","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/ijms19030893","volume":"19","author":"JJ D\u00edez","year":"2018","unstructured":"D\u00edez JJ, Sangiao-Alvarellos S, Cordido F (2018) Treatment with growth hormone for adults with growth hormone deficiency syndrome: benefits and risks. Int J Mol Sci 19:893.\u00a0https:\/\/doi.org\/10.3390\/ijms19030893","journal-title":"Int J Mol Sci"},{"key":"1283_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/j.1365-2265.2011.04137.x","volume":"75","author":"HJ Schneider","year":"2011","unstructured":"Schneider HJ, Klotsche J, Wittchen HU, Stalla GK, Schopohl J, Kann PH, Kreitschmann-Andermahr I, Wallaschofski H (2011) Effects of growth hormone replacement within the KIMS survey on estimated cardiovascular risk and predictors of risk reduction in patients with growth hormone deficiency. Clin Endocrinol (Oxf) 75:825\u2013830. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04137.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1283_CR5","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1210\/jc.2011-0179","volume":"96","author":"ME Molitch","year":"2011","unstructured":"Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML (2011) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1587\u20131609. https:\/\/doi.org\/10.1210\/jc.2011-0179","journal-title":"J Clin Endocrinol Metab"},{"key":"1283_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2337\/dc11-0449","volume":"35","author":"A Luger","year":"2012","unstructured":"Luger A, Mattsson AF, Koltowska-H\u00e4ggstr\u00f6m M, Thunander M, G\u00f3th M, Verhelst J, Abs R (2012) Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-deficient subjects during growth hormone replacement therapy: a long-term observational study. Diabetes Care 35:57-62.\u00a0https:\/\/doi.org\/10.2337\/dc11-0449","journal-title":"Diabetes Care"},{"key":"1283_CR7","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1507\/endocrj.ej15-0337","volume":"62","author":"L Giovannini","year":"2015","unstructured":"Giovannini L, Tirabassi G, Muscogiuri G, Di Somma C, Colao A, Balercia G (2015) Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk [Review]. Endocr J 62:1037\u20131048. https:\/\/doi.org\/10.1507\/endocrj.ej15-0337","journal-title":"Endocr J"},{"key":"1283_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1210\/er.2008-0027","volume":"30","author":"N M\u00f8ller","year":"2009","unstructured":"M\u00f8ller N, J\u00f8rgensen JO (2009) Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30:152\u2013177. https:\/\/doi.org\/10.1210\/er.2008-0027","journal-title":"Endocr Rev"},{"key":"1283_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2265.2009.03612.x","volume":"72","author":"WW Woodmansee","year":"2010","unstructured":"Woodmansee WW, Hartman ML, Lamberts SW, Zagar AJ, Clemmons DR (2010) Occurrence of impaired fasting glucose in GH-deficient adults receiving GH replacement compared with untreated subjects. Clin Endocrinol 72:59\u201369.\u00a0https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03612.x","journal-title":"Clin Endocrinol"},{"key":"1283_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1046\/j.1365-2265.2002.01601.x","volume":"57","author":"K Yuen","year":"2002","unstructured":"Yuen K, Cook D, Ong K, Chatelain P, Fryklund L, Gluckman P, Ranke MB, Rosenfeld R, Dunger D (2002) The metabolic effects of short-term administration of physiological versus high doses of GH therapy in GH deficient adults. Clin Endocrinol 57:333\u2013341.\u00a0https:\/\/doi.org\/10.1046\/j.1365-2265.2002.01601.x","journal-title":"Clin Endocrinol"},{"key":"1283_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s11102-020-01079-3","volume":"24","author":"H Zhou","year":"2021","unstructured":"Zhou H, Sun L, Zhang S, Wang Y, Wang G (2021) Effect of long-term growth hormone replacement on glucose metabolism in adults with growth hormone deficiency: a systematic review and meta-analysis. Pituitary 24:130\u2013142.\u00a0https:\/\/doi.org\/10.1007\/s11102-020-01079-3","journal-title":"Pituitary"},{"key":"1283_CR12","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1210\/jc.2012-2684","volume":"98","author":"ML Hartman","year":"2013","unstructured":"Hartman ML, Xu R, Crowe BJ, Robison LL, Erfurth EM, Kleinberg DL, Zimmermann AG, Woodmansee WW, Cutler GB Jr, Chipman JJ, Melmed S (2013) Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. J Clin Endocrinol Metab 98:980\u2013988.\u00a0https:\/\/doi.org\/10.1210\/jc.2012-2684","journal-title":"J Clin Endocrinol Metab"},{"key":"1283_CR13","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1507\/endocrj.ej13-0083","volume":"60","author":"A Shimatsu","year":"2013","unstructured":"Shimatsu A, Tai S, Imori M, Ihara K, Taketsuna M, Funai J, Tanaka T, Teramoto A, Irie M, Chihara K (2013) Efficacy and safety of growth hormone replacement therapy in Japanese adults with growth hormone deficiency: a post-marketing observational study. Endocr J 60:1131\u20131144.\u00a0https:\/\/doi.org\/10.1507\/endocrj.ej13-0083","journal-title":"Endocr J"},{"key":"1283_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/cen.13256","volume":"86","author":"M Weber","year":"2017","unstructured":"Weber M, Biller BM, Pedersen BT, Pournara E, Christiansen JS, Hoybye C (2017) The effect of growth hormone (GH) replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency: real-life data from the NordiNet(R) International Outcome Study. Clin Endocrinol (Oxf) 86:192\u2013198. https:\/\/doi.org\/10.1111\/cen.13256","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1283_CR15","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1210\/jc.2011-0448","volume":"96","author":"AF Attanasio","year":"2011","unstructured":"Attanasio AF, Jung H, Mo D, Chanson P, Bouillon R, Ho KK, Lamberts SW, Clemmons DR (2011) Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis. J Clin Endocrinol Metab 96:2255\u20132261. https:\/\/doi.org\/10.1210\/jc.2011-0448","journal-title":"J Clin Endocrinol Metab"},{"key":"1283_CR16","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.2337\/dc22-S002","volume":"45","author":"B Draznin","year":"2022","unstructured":"Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, Leon J, Lyons SK, Peters AL, Prahalad P, Reusch JEB, Young-Hyman D, Das S, Kosiborod M (2022) 2. classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care. 45:S17\u2013S38.\u00a0https:\/\/doi.org\/10.2337\/dc22-s002","journal-title":"Diabetes Care"},{"key":"1283_CR17","doi-asserted-by":"crossref","unstructured":"Carmina ESF, Lobo RA (2019) Evaluation of hormonal status. In: Strauss JF, Barbieri RL (eds) Yen and Jaffe\u2019s reproductive endocrinology, 8th edn. Elsevier, Philadelphia, p\u00a0887\u2013915.e4. http:\/\/herbex.tn\/pdf\/966\/945_PCOS911.pdf","DOI":"10.1016\/B978-0-323-47912-7.00034-2"},{"key":"1283_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.6065\/apem.2017.22.3.145","volume":"22","author":"SH Kim","year":"2017","unstructured":"Kim SH, Park MJ (2017) Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab. 22:145\u2013152.\u00a0https:\/\/doi.org\/10.6065\/apem.2017.22.3.145","journal-title":"Ann Pediatr Endocrinol Metab."},{"key":"1283_CR19","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.4158\/gl-2019-0405","volume":"25","author":"KCJ Yuen","year":"2019","unstructured":"Yuen KCJ, Biller BMK, Radovick S, Carmichael JD, Jasim S, Pantalone KM, Hoffman AR (2019) American association of clinical endocrinologists and American college of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract 25:1191\u20131232. https:\/\/doi.org\/10.4158\/gl-2019-0405","journal-title":"Endocr Pract"},{"key":"1283_CR20","doi-asserted-by":"publisher","first-page":"e1358","DOI":"10.1210\/clinem\/dgaa049","volume":"105","author":"G Johannsson","year":"2020","unstructured":"Johannsson G, Gordon MB, H\u00f8jby Rasmussen M, H\u00e5konsson IH, Karges W, Sv\u00e6rke C, Tahara S, Takano K, Biller BMK (2020) Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial. J Clin Endocrinol Metab. 105:e1358\u2013e1376.\u00a0https:\/\/doi.org\/10.1210\/clinem\/dgaa049","journal-title":"J Clin Endocrinol Metab"},{"key":"1283_CR21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-17-1073","volume":"178","author":"G Johannsson","year":"2018","unstructured":"Johannsson G, Feldt-Rasmussen U, H\u00e5konsson IH, Biering H, Rodien P, Tahara S, Toogood A, Rasmussen MH (2018) Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial. Eur J Endocrinol 178:491\u2013499.\u00a0https:\/\/doi.org\/10.1530\/EJE-17-1073","journal-title":"Eur J Endocrinol"},{"key":"1283_CR22","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/cen.14273","volume":"93","author":"F Otsuka","year":"2020","unstructured":"Otsuka F, Takahashi Y, Tahara S, Ogawa Y, H\u00f8jby Rasmussen M, Takano K (2020) Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone. Clin Endocrinol (Oxf) 93:620\u2013628. https:\/\/doi.org\/10.1111\/cen.14273","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1283_CR23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1210\/clinem\/dgaa775","volume":"106","author":"R Juul Kildemoes","year":"2021","unstructured":"Juul Kildemoes R, H\u00f8jby Rasmussen M, Agers\u00f8 H, Overgaard RV (2021) Optimal monitoring of weekly IGF-I levels during growth hormone therapy with once-weekly somapacitan. J Clin Endocrinol Metab 106:567\u2013576. https:\/\/doi.org\/10.1210\/clinem\/dgaa775","journal-title":"J Clin Endocrinol Metab"},{"key":"1283_CR24","unstructured":"Polonsky KS, B.C.: Chapter 31 - Type 2 Diabetes Mellitus. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM (eds). Williams Textbook of Endocrinology (13th Edition). Philadelphia: Elsevier. 1387 (2016)."},{"key":"1283_CR25","unstructured":"Weir, C.B.,Jan, A.: BMI Classification Percentile And Cut Off Points. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2022, StatPearls Publishing LLC.; 2022."},{"key":"1283_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.metabol.2007.08.015","volume":"57","author":"MC Cenci","year":"2008","unstructured":"Cenci MC, Concei\u00e7\u00e3o FL, Soares DV, Spina LD, Brasil RR, Lobo PM, Michmacher E, Vaisman M (2008) Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone-deficient adults. Metabolism 57:121\u2013129. https:\/\/doi.org\/10.1016\/j.metabol.2007.08.015","journal-title":"Metabolism"},{"key":"1283_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.7326\/0003-4819-133-2-200007180-00010","volume":"133","author":"G Sesmilo","year":"2000","unstructured":"Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A (2000) Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 133:111\u2013122","journal-title":"Ann Intern Med"},{"key":"1283_CR28","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1210\/jcem.86.10.7887","volume":"86","author":"G G\u00f6therstr\u00f6m","year":"2001","unstructured":"G\u00f6therstr\u00f6m G, Svensson J, Koranyi J, Alpsten M, Bosaeus I, Bengtsson B, Johannsson G (2001) A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 86:4657\u20134665. https:\/\/doi.org\/10.1210\/jcem.86.10.7887","journal-title":"J Clin Endocrinol Metab"},{"key":"1283_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ghir.2011.01.001","volume":"21","author":"AP J\u00f8rgensen","year":"2011","unstructured":"J\u00f8rgensen AP, Fougner KJ, Ueland T, Gudmundsen O, Burman P, Schreiner T, Bollerslev J (2011) Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency. Growth Horm IGF Res 21:69\u201375. https:\/\/doi.org\/10.1016\/j.ghir.2011.01.001","journal-title":"Growth Horm IGF Res"},{"key":"1283_CR30","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nrendo.2013.64","volume":"9","author":"DE Berryman","year":"2013","unstructured":"Berryman DE, Glad CA, List EO, Johannsson G (2013) The GH\/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. Nat Rev Endocrinol 9:346\u2013356. https:\/\/doi.org\/10.1038\/nrendo.2013.64","journal-title":"Nat Rev Endocrinol"},{"key":"1283_CR31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/s2213-8587(19)30084-1","volume":"7","author":"IJ Neeland","year":"2019","unstructured":"Neeland IJ, Ross R, Despr\u00e9s JP, Matsuzawa Y, Yamashita S, Shai I, Seidell J, Magni P, Santos RD, Arsenault B, Cuevas A, Hu FB, Griffin B, Zambon A, Barter P, Fruchart JC, Eckel RH (2019) Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol 7:715\u2013725. https:\/\/doi.org\/10.1016\/s2213-8587(19)30084-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1283_CR32","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1210\/jc.2010-2819","volume":"96","author":"BM Biller","year":"2011","unstructured":"Biller BM, Ji HJ, Ahn H, Savoy C, Siepl EC, Popovic V, Coculescu M, Roemmler J, Gavrila C, Cook DM, Strasburger CJ (2011) Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency. J Clin Endocrinol Metab 96:1718\u20131726. https:\/\/doi.org\/10.1210\/jc.2010-2819","journal-title":"J Clin Endocrinol Metab"},{"key":"1283_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s11102-012-0422-8","volume":"16","author":"BM Biller","year":"2013","unstructured":"Biller BM, Ji HJ, Ahn H, Savoy C, Siepl EC, Popovic V, Coculescu M, Roemmler J, Gavrila C, Cook DM, Strasburger CJ (2013) 12-month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency. Pituitary 16:311\u2013318. https:\/\/doi.org\/10.1007\/s11102-012-0422-8","journal-title":"Pituitary"},{"key":"1283_CR34","doi-asserted-by":"publisher","first-page":"6431","DOI":"10.1210\/jc.2005-0928","volume":"90","author":"AR Hoffman","year":"2005","unstructured":"Hoffman AR, Biller BM, Cook D, Baptista J, Silverman BL, Dao L, Attie KM, Fielder P, Maneatis T, Lippe B (2005) Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. J Clin Endocrinol Metab 90:6431\u20136440. https:\/\/doi.org\/10.1210\/jc.2005-0928","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01283-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-022-01283-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01283-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T13:13:29Z","timestamp":1675948409000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-022-01283-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1283"],"URL":"https:\/\/doi.org\/10.1007\/s11102-022-01283-3","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"assertion":[{"value":"7 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YT has received honoraria from Novo Nordisk, Novartis, Eli Lilly, Recordati Rare Disease, Otsuka Pharma and Ascendis Pharma and has received grant support from Ono Pharma, Teijin Pharma, Novo Nordisk, Kowa Pharma, Taisho Pharma, Daiichi Sankyo Pharma and Tanabe Mitsubishi Pharma. BMKB has served as the PI of grants to Massachusetts General Hospital over the last 3\u00a0years from: Ascendis, Crinetics, Ionis, Millendo, Novartis and Strongbridge and has been an occasional consultant over the last 3\u00a0years to Aeterna Zentaris, Ascendis, Crinetics, HRA Pharma, Ipsen, EMD Serono, Novartis, Novo Nordisk, Recordati, Sparrow, Strongbridge and Xeris. HF declares no funding for this paper. KH serves as an advisor to Novo Nordisk and Ipsen. MHR is an employee of and stockholder in Novo Nordisk. NN is an employee of Novo Nordisk. CS is an employee of and stockholder in Novo Nordisk. KY has received research grants to Barrow Neurological Institute from Ascendis, Crinetics, Amryt and Corcept. Served as an occasional advisory board member for Novo Nordisk, Ascendis, Sandoz, Corcept, Ipsen, Amryt, Strongbridge, Crinetics, Xeris and Recordati. Served as occasional speaker for Novo Nordisk, Recordati and Corcept. GJ has received lecture fees from Merck Serono, Novartis, Novo Nordisk, Otsuka, Pfizer, and Sandoz, as well as consultancy fees from Astra Zeneca, Novo Nordisk and Shire.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures involving human participants performed in these studies were in accordance with the ethical standards of the institutional and\/or national research committee and with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"REAL 1, REAL 2 and REAL Japan were approved by the relevant local and national ethics committees, and conducted with written consent from all patients in accordance with the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}